The Drug-Induced Respiratory Disease Website
Philippe Camus, M.D.
Browse by »
Pulmonary arterial hypertension
Will reverse in some patients upon drug discontinuance
Last update :
No medias available.
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
American journal of hematology 2015 Nov;90;1060-4 2015 Nov
Dasatinib-Induced Pulmonary Arterial Hypertension.
British journal of clinical pharmacology 2018 Jan 15;; 2018 Jan 15
Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition.
The European respiratory journal 2013 Sep;42;869-70 2013 Sep
Dasatinib-induced pulmonary hypertension in chronic myelogenous leukaemia.
BMJ case reports 2014 Apr 15;2014; 2014 Apr 15
Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia.
The European respiratory journal 2011 Jul;38;218-20 2011 Jul
Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study.
The European respiratory journal 2017 Jul;50; 2017 Jul
Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
BMC pulmonary medicine 2011 May 23;11;30 2011 May 23
Progressive arterial occlusive disease (PAOD) and pulmonary arterial hypertension (PAH) as new adverse events of second generation TKIs in CML treatment: who's afraid of the big bad wolf?
Leukemia research 2012 Jul;36;813-4 2012 Jul
Pulmonary arterial hypertension caused by treatment with dasatinib for chronic myeloid leukemia -critical alert-.
Internal medicine (Tokyo, Japan) 2012;51;2337-40 2012
Pulmonary arterial hypertension in patients treated by dasatinib.
Circulation 2012 May 01;125;2128-37 2012 May 01
Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib.
Herz 2013 Dec;38;931-3 2013 Dec
Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient.
Bone marrow transplantation 2009 Jun;43;967-8 2009 Jun
Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia.
Leukemia research 2012 Jan;36;e4-6 2012 Jan